We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?
Introduction Progress toward hepatitis C virus (HCV) elimination is impeded by low testing
and treatment due to the current diagnostic pathway requiring multiple visits leading to loss …
and treatment due to the current diagnostic pathway requiring multiple visits leading to loss …
The urgent need to implement point-of-care RNA testing for hepatitis C virus to support elimination
Hepatitis C virus (HCV) elimination is an important global public health goal. However, the
United States is not on track to meet the World Health Organization's 2030 targets for HCV …
United States is not on track to meet the World Health Organization's 2030 targets for HCV …
Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis
MJ Hayes, E Beavon, MW Traeger, JF Dillon… - …, 2024 - thelancet.com
Summary Background The World Health Organization seeks to eliminate viral hepatitis as a
public health threat by 2030. This review and meta-analysis aims to evaluate the …
public health threat by 2030. This review and meta-analysis aims to evaluate the …
Point-of-Care Testing for Hepatitis C in the Priority Settings of Mental Health, Prisons, and Drug and Alcohol Facilities—the PROMPt Study
EM McCartney, L Ralton, J Dawe… - Clinical Infectious …, 2024 - academic.oup.com
Background A barrier to hepatitis C virus (HCV) cure is conventional testing. The aim of this
study was to evaluate the effect of HCV antibody and RNA point-of-care testing (POCT) on …
study was to evaluate the effect of HCV antibody and RNA point-of-care testing (POCT) on …
Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically …
MB MacIsaac, B Whitton, J Anderson, S Cogger… - International Journal of …, 2024 - Elsevier
Background To achieve hepatitis C virus (HCV) elimination targets, simplified care engaging
people who inject drugs is required. We evaluated whether fingerstick HCV RNA point-of …
people who inject drugs is required. We evaluated whether fingerstick HCV RNA point-of …
Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service …
G Fontaine, J Presseau, J Bruneau… - International Journal for …, 2024 - Springer
Abstract Background Hepatitis C virus (HCV) infection is a significant global health burden,
particularly among people who inject drugs. Rapid point-of-care HCV testing has emerged …
particularly among people who inject drugs. Rapid point-of-care HCV testing has emerged …
'I just never wanted them to feel uncomfortable': Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada
M Selfridge, T Barnett, K Lundgren… - Canadian Liver …, 2024 - canlivj.utpjournals.press
Background: Canada is currently on target to reach the 2030 WHO goal of HCV elimination.
Continued high rates of treatment are required to meet this goal. Novel models such as …
Continued high rates of treatment are required to meet this goal. Novel models such as …
It may take many villages, but progress can be made toward HCV elimination among people who inject drugs
K Page - The Lancet Regional Health–Americas, 2023 - thelancet.com
Treatment barriers continue to limit provision and uptake of highly effective treatment for
many people with chronic hepatitis C virus (HCV) infection. In the United States, notable …
many people with chronic hepatitis C virus (HCV) infection. In the United States, notable …
Promoting Equity in Hepatitis C Care: A Qualitative Study Using an Intersectionality Lens to Explore Barriers and Facilitators to Point-of-Care Testing Among People …
Background: Hepatitis C virus (HCV) infection is a significant global health burden,
particularly among people who inject drugs. Rapid point-of-care HCV testing has emerged …
particularly among people who inject drugs. Rapid point-of-care HCV testing has emerged …
Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting
E Yela, N Solé, L Puig, D López Gallegos… - Harm Reduction …, 2024 - Springer
Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject
drugs in the community setting. Qualitative study with prison population. Hepatitis C (HCV) …
drugs in the community setting. Qualitative study with prison population. Hepatitis C (HCV) …